Cardiovascular revascularization medicine : including molecular interventions · 2026
Long-term causes of death in patients who underwent mitral transcatheter edge-to-edge repair.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Popolo Rubbio Antonio, Celeski Mihail, Sisinni Antonio, Guerrini Marco, Barletta Marta, Mainardi Chiara, Cannone Gaspare, Desimone Pietro, Nicodemo Antonino A, Brambilla Nedy, Tusa Maurizio, Bedogni Francesco, Testa Luca
Аннотация
BACKGROUND: Transcatheter mitral edge-to-edge repair (M-TEER) has transformed the management of patients with severe mitral regurgitation (MR) at high or prohibitive surgical risk. However, data on long-term survival and causes of death after M-TEER remain limited.
METHODS AND RESULTS: This single-center registry included consecutive patients undergoing M-TEER with the MitraClip device for severe MR between February 2016 and June 2020. The primary objective was long-term mortality trends and causes of death. Over a median follow-up of 3.3 years (IQR 1.3-5.1; maximum 8.5 years), 130 of 218 patients (59.6%) died, with 55.4% due to cardiovascular (CV) causes, mainly heart failure (HF, 34.6%). Non-CV deaths were attributed to sepsis (15.4%), malignancy (10.8%), trauma (3.8%), and multi-organ failure (1.5%). CV mortality accounted for 55% of deaths within 1 year and 68.4% beyond 5 years, with no significant change in the CV/non-CV mortality ratio over time. Among 88 survivors, non-fatal CV events were infrequent: 12.5% were rehospitalized for HF and 2.3% underwent repeat M-TEER. Non-CV hospitalizations occurred in 9.1%, mainly due to fractures or pneumonia. Independent predictors of all-cause mortality included ischemic secondary MR etiology, prior HF, TAPSE/sPAP ≤0.36, and ≥moderate tricuspid regurgitation, while a low MitraScore predicted better survival. A low MitraScore risk was associated with a significantly lower all-cause and CV mortality compared to a high Mitrascore risk (48.6% vs 83.9%, p < 0.001; 21.0% vs 64.4%, p ≤ 0.001).
CONCLUSION: Long-term mortality after M-TEER remains influenced by extra-mitral cardiac involvement and non-cardiac comorbidities. The MitraScore preserves its prognostic accuracy during extended follow-up.
METHODS AND RESULTS: This single-center registry included consecutive patients undergoing M-TEER with the MitraClip device for severe MR between February 2016 and June 2020. The primary objective was long-term mortality trends and causes of death. Over a median follow-up of 3.3 years (IQR 1.3-5.1; maximum 8.5 years), 130 of 218 patients (59.6%) died, with 55.4% due to cardiovascular (CV) causes, mainly heart failure (HF, 34.6%). Non-CV deaths were attributed to sepsis (15.4%), malignancy (10.8%), trauma (3.8%), and multi-organ failure (1.5%). CV mortality accounted for 55% of deaths within 1 year and 68.4% beyond 5 years, with no significant change in the CV/non-CV mortality ratio over time. Among 88 survivors, non-fatal CV events were infrequent: 12.5% were rehospitalized for HF and 2.3% underwent repeat M-TEER. Non-CV hospitalizations occurred in 9.1%, mainly due to fractures or pneumonia. Independent predictors of all-cause mortality included ischemic secondary MR etiology, prior HF, TAPSE/sPAP ≤0.36, and ≥moderate tricuspid regurgitation, while a low MitraScore predicted better survival. A low MitraScore risk was associated with a significantly lower all-cause and CV mortality compared to a high Mitrascore risk (48.6% vs 83.9%, p < 0.001; 21.0% vs 64.4%, p ≤ 0.001).
CONCLUSION: Long-term mortality after M-TEER remains influenced by extra-mitral cardiac involvement and non-cardiac comorbidities. The MitraScore preserves its prognostic accuracy during extended follow-up.